Healthcare - Articles
Today's edition of DailyUpdates features work conducted by Imperial College researchers who have identified an aptamer able to reduce the proliferation of lymphoma cells by 40%. This work represents a licensing opportunity. The aptamer is of potential therapeutic use and may be of interest to compan…
Although COPD is a devastating disease affecting an estimated one in 10 people aged 45 and older, up to 80% of sufferers are unaware they have it. Furthermore, even for patients who do receive treatment, current therapies do not stop the disease's progression. Until better treatments are available, then, efforts must focus on improving smoking cessation therapies and increasing awareness of COPD. …
A devastating disease with a poor prognosis for many patients, until recently CML has had few treatment options and, for the most part, these have succeeded only in delaying disease progression by up to a few years. Chronic myeloid leukaemia (CML) is a myeloproliferative disorder affecting 1 to 2 people per 100,000 annually. These disorders…
The prevalence of obesity has increased by 61% in the during the period 1991-2001. According to Datamonitor’s report, Obesity - commercial opportunities and therapeutic pipeline analysis 127m people were classified obese in the seven major markets in 2003. Even though there is an increasing awarene…
Dementia is a neurodegenerative and devastating disease Dementia is a degenerative disease of the brain that progressively destroys the neurons controlling memory, language and reasoning. It progresses at different rates in different people. It is estimated that dementia currently affects nearly 18 million people worldwide (1). As the mean age of the population increases, these numbers are steadily increasing. Forms of dementia and their estimated prevalence: 1 Alzheimer's disease (AD) 55% Vascular dementia (VaD)20% Dementia with Lewy bodies (DLB) and dementia…
DailyUpdates 3rd February, 2006: The size of the cytotoxic market in the seven major pharmaceutical markets is estimated to be approximately $9.6 billion. Datamonitor expects it to reach a peak of $12.8 billion by 2009. However, mainly due to major patent expiries, it is expected to drop to $11.3 bi…
The market for antibacterials, valued at $24 billion in the seven major markets, faces significant revenue loss in the period 2005-2007 due to major patent expiries (see Commercial Insight: Antibacterials). Despite the problems faced by companies involved in antibacterials considerable success has been met by th…
DailyUpdates Jan 31st: OX40:OX40L interaction – evolving from a key component of autoimmunity to a possible target for cardiovascular disease OX40 (CD134) is one of the newer tumor necrosis factor receptor (TNFR) family members. Expressed on CD4+ T-cells, its activation by OX40L, a type II membrane protein expressed on activated B-cells, dendritic cells and macrophages, plays an important T-cell co-stimulatory role. In our recent feature on Autoimmun…
Source DailyUpdates Jan 25th: As information technology becomes increasingly important in drug R&D, the application of bioinformatics/informatics applications has the potential to drive growth in the worldwide pharmaceuticals drug market from the $240 billion today to $3 trillion by 2020.The role of bioinformatics/informatics in the drug d…
In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases…
At least five phase II and six phase I DPP-IV inhibitors are closely following and more than 10 further companies are in advanced preclinical R&D. Available data show differences in duration of action and anticipated dosing frequency, whereas data to compare clinical efficacy and safety presently is not available. The high interest of the pharmaceutical industry reflects the market attractivity. The WHO estimates that globally over 170 mln people have diabetes, with type 2 diabetes accounting for 90 % to 95 %. By 2030, the prev…
A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs…
By: Brian S. Robinson i3, Vice-President, Global Marketing www.i3global.com There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful. Speed is not a capabili…
Bill McHale and Iain Jessup – i3 Pharma Resourcing Perhaps the greatest challenge facing global drug development is the scarcity of new clinical research professionals entering the industry, bringing refreshing energy and ideas to their work, but lacking practical experience. Those involved in recruiting CR staff will be aware of this shortage and that experienced employees are seeking gr…
Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes. But what is the reality, and where is the border between the promise of providers and the expectation of end users? This article is not designed to provide d…
If you are a UK registered charity in the healthcare sector, we can offer you FREE job postings. So, you can access 160,000 visitors per month for nothing! If you want to know more contact Mike Wood
As part of our continuing development and improvement, we have added created a Blog of our Top Jobs. This will be updated weekly and will also include any other news or information we think is relevant relevant to Pharmaceutical job searching. Check it out here: http://pharmaceuticaljobs.blogspot.com/
Dr Adam Meijer of the Netherlands-based European Influenza Surveillance Scheme (EISS)§ has highlighted the vital role rapid testing must play in combating the global threat of bird flu. Dr Meijer makes his observations in the January issue of Expert Review of Molecular Diagnostics. Until now, the last requirement for avian influenza viruses to cause a pandemic – efficient transmission between humans – has fortunately not been met. However, the devastating effect of the A(H5N1) bird flu on poultry holdings, and he…
New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration. Iron was removed from the blood and tissues of patients just as safely and effectively with the novel once-daily oral chelator treatment deferasirox (Exjade) as with the standard older injectable iron chelator deferoxamine. Th…
Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study. Before availability of current treatments, median survival from diagnosis was 3.5 years. Around 95 pe…